Prognosis of distal pancreatic cancers controlled by stage
Prognosis of distal pancreatic cancers controlled by stage
复制标题
DOI：
10.3892/etm.2020.8795
复制
发表时间：
2020-08-01
影响因子：
2.7
通讯作者：
Yu, Xianjun
中科院分区：
文献类型：
--
作者：
Luo, Guopei;Jin, Kaizhou;Yu, Xianjun
研究发现，远端（体/尾）胰腺癌患者的预后比头部癌症患者差，这通常归因于体/尾癌在检测时大部分处于晚期。然而，分期控制的头胰腺癌和体尾胰腺癌的预后差异尚未得到深入分析。在这项研究中，使用监测、流行病学和最终结果计划 (SEER)（1973-2014 年登记，85,715 例）检查了头胰腺癌和体尾胰腺癌之间的预后差异。我们发现，在所有组合分期中，体尾胰腺癌患者的预后均比头癌患者差[调整后的风险比 (HR)，1.03，95% 置信区间 (CI)，1.00-1.05，P=0.025]。与头癌患者相比，体/尾癌患者 I 期癌症死亡率较低（HR，0.85，95% CI，0.76-0.94，P=0.001），II 期或 III 期癌症死亡率无差异（II 期，HR，1.00，95% CI，0.95-1.06，P=0.965；III 期，0.97，95% CI， 0.91-1.04，P=0.398），IV 期死亡率较高（HR，1.07，95% CI，1.04-1.10，P
Patients with distal (body/tail) pancreatic cancer have been found to present worse outcome than patients with head cancer, which is generally attributed to the great proportion of advanced stages for body/tail cancers upon detection. However, differences in prognosis between head and body/tail pancreatic cancers controlled by stage have not been analyzed in-depth. In this study, differences in prognosis between head and body/tail pancreatic cancers were examined using the Surveillance, Epidemiology, and End Results Program (SEER) (1973-2014 registry, 85,715 cases). We found that patients with body/tail pancreatic cancer had worse prognosis than patients with head cancer for all combined stages [adjusted hazard ratio (HR), 1.03, 95% confidence interval (CI), 1.00-1.05, P=0.025]. Compared with patients with head cancer, patients with body/tail cancer had lower mortality for stage I cancers (HR, 0.85, 95% CI, 0.76-0.94, P=0.001), no difference in mortality for stages II or III (stage II, HR, 1.00, 95% CI, 0.95-1.06, P=0.965; stage III, 0.97, 95% CI, 0.91-1.04, P=0.398), and higher mortality for stage IV (HR, 1.07, 95% CI, 1.04-1.10, P